In 2000, the pharmaceutical industry (English expression: Medical Industry) completed the total output value of 233.2 billion yuan, with an average annual growth rate of 17.5%, higher than the Ninth Five-Year Plan target of 15%. Realize industrial added value of 57.8 billion yuan, an average annual growth rate of 15.5%. Pharmaceutical commercial sales totaled 150.9 billion yuan, an increase of 70.5 billion yuan over 1995, an average annual growth rate of 13.4%. The total import and export of pharmaceutical commodities amounted to 6.4 billion U.S. dollars, of which: exports of 3.8 billion U.S. dollars, an increase of 800 million U.S. dollars over 1995, an average annual growth rate of 4.8%, the pharmaceutical export-oriented economy is gradually taking shape. Pharmaceutical industry to realize total profits and taxes 27 billion yuan, an increase of 15.5 billion yuan over 1995, an average annual growth rate of 18.6%, to achieve a profit of 14.38 billion yuan, an increase of 9.43 billion yuan over 1995, an average annual growth rate of 24.5%, both exceeded the Ninth Five-Year Plan to determine the target of 18%. Pharmaceutical business to realize profits of 760 million yuan, an increase of 400 million yuan over 1995, an average annual growth rate of 16.1%. Pharmaceutical industry has realized the benefits of growth faster than the total growth of the situation, the economic growth mode began to change.
The sales of the third terminal have reached 101.4 billion yuan in 2009, an increase of 26.7% year-on-year.
August 2010, the pharmaceutical industry revenue and total profit year-on-year growth rate of 25.69%, 34.71%. 2. The structure of the pharmaceutical economy has improved.
In the fierce market competition, the pharmaceutical industry through various forms of union, mergers and reorganization, to a certain extent, to change the pharmaceutical enterprises are too small, the layout of the situation of over-dispersed, and improve the concentration of production. Pharmaceutical industry has 25 enterprises into the ranks of the country's 520 large enterprises. The production concentration of the top 60 enterprises in the pharmaceutical industry sales is 35.7%, which is 16 percentage points higher than the 19.7% at the end of the 8th Five-Year Plan, and a number of advantageous brand-name enterprises have gradually developed and grown in the fierce market competition. The number of enterprises producing large-tonnage products such as penicillin, vitamin C, synthetic vitamin E, aspirin, paracetamol, etc. has been greatly reduced. The production concentration of the top 50 producers of the 5 major categories of tablets, powder injections, water injections, infusions and capsules reached 44.3%, 97.6%, 66.5%, 58.9% and 56.2% respectively.
The ownership structure has been further adjusted, basically forming a pattern of public ownership as the mainstay and multiple ownership economies*** developing together. The proportion of joint-stock economy in the whole industry has risen to 33.2% from 12% in the early stage of the Ninth Five-Year Plan, the three-funded economy has risen to 18.8% from 15%, and the state-owned economy has declined to 36.1% from 55%.
Pharmaceutical distribution system reform accelerated the pace of pharmaceutical business to break the long-planned economic system under the formation of the state-owned business dominance pattern, the property rights structure to the direction of diversification, the formation of a number of more standardized shareholding system enterprises and large-scale enterprise groups. The mode of operation began to change, general agent, general distribution, centralized distribution, chain management and other new business practices continue to emerge, especially the chain management in the Ninth Five-Year Plan period has been a large development, the country has established in some large and medium-sized cities nearly 200 pharmaceutical chain enterprises, chain management of more than 5,000 drugstores. A number of enterprises have actively explored and piloted pharmaceutical e-commerce.
The western region of the pharmaceutical economy has made great progress. Sichuan has become China's traditional Chinese medicine production province, Yunnan, Guizhou, Qinghai, Gansu, Inner Mongolia, Guangxi and other provinces and regions to give full play to the advantages of local resources, has become China's national medicine production base, promoting the local economic development, optimize the regional economic structure. 3. Science and education to develop medicine has made certain achievements.
Pharmaceutical industry to implement the policy of science and education to develop drugs, increased research and development of new products, new products in 1999, the output value of 15.8%. During the Ninth Five-Year Plan period, China's pharmaceutical enterprises and scientific research units*** obtained 5043 certificates of new drugs of all kinds, involving 2112 varieties, including 108 certificates of new drugs of the first class.
Clinical efficacy, low toxicity and side effects of beta-lactam series of products in the antibiotic class of chemical raw materials in the proportion of the end of the 8th Five-Year Plan by 15.3% to the end of 1999, 20.3%; some of the shortage of key intermediates for pharmaceutical specialties, such as 6-amino-penicillinic acid (6-APA), 7-amino-cephalosporanic acid (7-APA). Some key intermediates in short supply, such as 6-aminopenicillanic acid (6-APA), 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporanic acid (7-ADCA), isophytol, trimethylhydroquinone, etc., have basically been substituted for imports. Natural vitamin E, roxithromycin, azithromycin and other important products have been industrialized, and new dosage forms such as controlled-release, slow-release and transdermal have been developed.
High-efficiency separation and purification technology, supercritical extraction technology, automatic control technology of the production process, microencapsulation and targeting technology and a number of high and new technologies have been popularized and applied in pharmaceutical production. Penicillin production rate has been increased from 0.7-0.8 tons/year at the end of 1985? Cubic meter fermentation volume increased to 1.0-1.1 tons, the total yield of vitamin C by the end of the eighty-fifth 48% to about 60%; dexamethasone production using the new process of biological dehydrogenation, a substantial reduction in costs, and improve the international competitiveness of not only to replace the imports, but also exported in large quantities.
The development of new products of traditional Chinese medicine has been accelerated, especially in the treatment and prevention of cardiovascular and cerebrovascular diseases, digestive system, hepatitis and other new varieties of breakthroughs. The Chinese medicine Xingling Granules and Salvia divinorum pills have passed the prequalification of the U.S. FDA (U.S. Food and Drug Administration) and entered the clinical trial, which is another step for the Chinese medicine to enter the international market. Tibetan medicine and other ethnic drugs have also gone from minority areas to the country.
The level of pharmaceutical equipment and production conditions have been greatly improved. During the Ninth Five-Year Plan period, there are a large number of advanced, applicable equipment such as double-loop flow gas-assisted fermentation reactor, dynamic extraction equipment, microporous membrane filters and other industrialization, and widely used in the pharmaceutical industry. A number of enterprises have passed ISO9000 certification. By the end of 2000, more than 780 pharmaceutical enterprises (workshops and dosage forms) had passed the GMP (Good Manufacturing Practice) certification, and the quality of medicines had improved.
Medical equipment in some of the high-precision, sharp products such as magnetic **** vibration, CT (X-ray computed tomography imaging device), color ultrasound, etc. to achieve industrialization, low and medium-energy linear gas pedal, such as the basic realization of the localization of the rotary gamma knife, digital subtraction imaging system, laser scaler, fiber-optic endoscopy, etc., can be mass production, in line with the international technical standards, the full Chinese direct digital X-ray medical imaging system in China has been successfully developed and put into clinical application, high-power carbon dioxide cardiac laser therapeutic instrument has been successfully developed and obtained a national patent. Medical device product standards are gradually in line with international standards, the procurement of parts and components has begun to realize the internationalization of supporting nearly 100 enterprises have passed ISO9000 certification. 4. Opening up to the outside world has made significant achievements.
Pharmaceutical industry is one of the earliest industries in China to open up to the outside world, but also the use of foreign capital is more successful industry. The world's top 20 pharmaceutical companies have invested in China to build factories. The pilot work of Chinese-foreign joint venture in pharmaceutical business is proceeding smoothly. The establishment of these three-funded enterprises, not only the introduction of capital, but also brought new products, new technologies, new equipment and new business methods and management concepts, the domestic enterprises have played a good role as a model.